Trial Profile
A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With RMS Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a (MAIN-MS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms MAIN-MS
- Sponsors Merck KGaA
- 10 Sep 2020 Status changed from active, no longer recruiting to completed.
- 18 Aug 2020 Planned End Date changed from 30 Jun 2020 to 30 Aug 2020.
- 18 Aug 2020 Planned primary completion date changed from 30 Jun 2020 to 30 Aug 2020.